Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer Boris Sepesi, MD, Kathryn A. Gold, MD,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

VATS Thymectomy with 3D Vision: A Chance to Further Improve the Outcomes of Thymus Minimally Invasive Surgery Federico Attene, MD, Fabrizio Scognamillo,

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

A Primer on Health Economic Evaluations in Thoracic Oncology

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Y. Lou, R. Manochakian, J. Cochuyt, D. Hodge, S. Ailawadhi

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD Journal of Thoracic Oncology Volume 12, Issue 10, Pages 1478-1488 (October 2017) DOI: 10.1016/j.jtho.2017.07.022 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Potential biological mechanisms contributing to the obesity paradox in lung cancer. Factors that may contribute to better prognosis in lung cancer include the following: (1) patients with metabolically healthy obesity or physiological fitness may not suffer from the detrimental effects of obesity-associated metabolic disturbance; (2) adipose tissue may provide greater physiological and nutritional reserves, thereby prolonging life by slowing the progress of cancer cachexia; and (3) some adipokines from the adipose tissue may produce tumor-suppressing effects and, therefore, survival advantages. However, the presence of cachexia and presence of sarcopenia, which are characterized by massive and progressive muscle and fat loss, are established as predictors of poor prognosis of lung cancer. These biological mechanisms may partially explain the inverse relationship between body mass index (BMI) and lung cancer outcome. Journal of Thoracic Oncology 2017 12, 1478-1488DOI: (10.1016/j.jtho.2017.07.022) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions